Phase 2 Chronic Kidney Disease Trial, Recruiting NCT04984226 Sponsor: University of California, Davis Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 2 Chronic Kidney Disease Trial, Recruiting

NCT04984226
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have moderate-to-severe chronic kidney disease, shown by kidney function test results below a certain level on at least two separate occasions
  • People who have a blood acid-base imbalance called metabolic acidosis, confirmed by blood test results on two separate occasions (the exact cutoff may vary depending on kidney function — confirm with trial site)
  • People aged between 21 and 85 years old

Who may not be able to join:

  • People with Type 1 diabetes
  • People whose diabetes is poorly controlled (based on a specific blood sugar average test result)
  • People with a history of ongoing high potassium levels in the blood
  • People with a history of ongoing low potassium levels in the blood
  • People with uncontrolled high blood pressure
  • People who are currently on dialysis or another form of kidney replacement therapy
  • People with a history of a torn main heart artery (aortic dissection) or severe heart valve disease
  • People who experience chest pain during exercise
  • People with an uncontrolled irregular heartbeat
  • People with severe lung disease (COPD) that requires ongoing oxygen use
  • People who experience significant leg pain when walking due to poor circulation (claudication)
  • People with end-stage liver disease
  • People who are unable to walk without another person's physical help
  • People with dementia or psychosis
  • People who are not able to give informed consent for themselves
  • People who are currently using intravenous (injected) drugs
  • People who do not speak English
  • People who have had an organ or tissue transplant
  • People who have metal implants or metal fragments in their body that would prevent an MRI scan
  • People who have a pacemaker
  • People who are expected to need to start dialysis before the trial is completed
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period
  • People with any other condition that the trial doctor considers would make participation unsafe (confirm with trial site)

Additional criteria for an optional muscle biopsy procedure within the trial:

  • People taking blood-thinning medications (such as warfarin, rivaroxaban, apixaban, dabigatran, or edoxaban) may not be eligible for the optional biopsy
  • People taking two or more antiplatelet medications (such as aspirin, clopidogrel, or similar) may not be eligible for the optional biopsy
  • People with a low platelet count or certain abnormal blood clotting results may not be eligible for the optional biopsy (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Baback Roshanravan, MD, UC Davis

Phone: 530-754-0893

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
8 September 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

muscle mitochondrial oxidative capacity by 31P MRS; Insulin sensitivity (SI) by insulin clamp; total work performed on cycle ergometry VO2; muscle work efficiency cycle ergometry; Walking endurance by 6-minute walk; FACIT-F Fatigue (PRO)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov